USE OF A COMBINATION OF АVASTIN AND LOW-DOSE INTERFERON- α IN THE FIRST-LINE TREATMENT OF METASTATIC RENAL-CELL CANCER

Authors: Kalpinsky A.S.¹^,2, Alekseyev B.Y.¹^,2, Kaprin A.D.¹^,2
Affiliations:
1. P.A. Herzen Moscow Oncology Research Institute
2. Peoples’ Friendship University of Russia, Moscow
Issue: Vol 9, No 3 (2013)
Pages: 30-36
Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER
Published: 30.09.2013
URL: https://oncourology.abvpress.ru/oncur/article/view/114
DOI: https://doi.org/10.17650/1726-9776-2013-9-3-30-36
ID: 114

Cite item

Full Text

metastatic renal-cell cancer, targeted therapy, angiogenesis inhibitors, bevacizumab, Avastin

P.A. Herzen Moscow Oncology Research Institute;
Peoples’ Friendship University of Russia, Moscow

Author for correspondence.
Email: dr.kalpinskiy@rambler.ru

Department of Urology with Course of Urologic Oncology

Russian Federation

P.A. Herzen Moscow Oncology Research Institute;
Peoples’ Friendship University of Russia, Moscow

Department of Urology with Course of Urologic Oncology

Russian Federation

P.A. Herzen Moscow Oncology Research Institute;
Peoples’ Friendship University of Russia, Moscow

Department of Urology with Course of Urologic Oncology

Russian Federation

Supplementary Files

Action

1. JATS XML